How much revenue does Celestra make?

Celestra reported 2.01 billion KRW in revenue for fiscal year 2025, down 76.4% from 8.50 billion KRW in fiscal year 2024.

What is Celestra's largest business segment?

Food and Food Service Business Division, with 4.63 billion KRW or 54% of segment revenue in fiscal year 2024. Next: Bio Business Division (46%) and Investment Business Division (under 1%).

Where does Celestra make most of its revenue?

South Korea: 94% of revenue by region in fiscal year 2024, followed by Other (5%).

What companies are similar to Celestra?

Listed companies of a similar size in the same industry (DNA testing equipment) include Gencurix Inc. (229000.KQ), Genesystem Co., Ltd. (363250.KQ), GeneMatrix Inc. (109820.KQ), NGeneBio Co., Ltd. (354200.KQ).

Celestra Inc. (352770.KQ) Stock

About Celestra Inc.

Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company's liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for tumor cells (CTCs), cell free DNA, and EV (e...

At a glance

Celestra reported revenue of 2.01 billion KRW for fiscal year 2025, down 76.4% from fiscal year 2024, and net income of -11.77 billion KRW. Its largest business segment, Food and Food Service Business Division, brought in 54% of segment revenue in fiscal year 2024; South Korea was the largest region with 94%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.